Coya Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Coya Therapeutics, Inc. director Mark H. Pavao acquired 10,000 stock options with an exercise price of $4.53, vesting over one year.
NASDAQ
Coya Therapeutics' Chief Financial Officer, David S. Snyder, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.
NASDAQ
Coya Therapeutics' Chief Medical Officer, Fred Grossman, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.
NASDAQ
Coya Therapeutics, Inc. has granted its Executive Chairman, Howard Berman, 15,257 stock options with an exercise price of $4.73, vesting over 36 months.
NASDAQ
Coya Therapeutics' CEO, Arun Swaminathan, was granted 293,983 stock options with an exercise price of $4.73, vesting over 36 months.
NASDAQ
Anabella Villalobos, a Director at Coya Therapeutics, Inc., was granted 10,000 stock options with an exercise price of $5.65, vesting on January 2, 2027.
NASDAQ
Coya Therapeutics Director Dov A. Goldstein MD was granted 10,000 stock options with an exercise price of $5.65, vesting in one year.
NASDAQ
Coya Therapeutics Director Dieter Weinand was granted 10,000 stock options with an exercise price of $5.65, vesting in one year.
NASDAQ
Coya Therapeutics Director Wilbur L. Ross Jr. was granted 10,000 stock options with an exercise price of $5.65, vesting fully on January 2, 2027.
NASDAQ
Coya Therapeutics Director Lee Ann was granted 10,000 stock options with an exercise price of $5.65, vesting on January 2, 2027.
NASDAQ
Coya Therapeutics Director Dov A. Goldstein, MD, reported a planned exercise of options to acquire 17,557 shares at $1.09 per share, effective August 18, 2025.
NASDAQ
Director Ann Lee acquires 5,000 stock options in Coya Therapeutics, Inc.
NASDAQ
Anabella Villalobos, a director of Coya Therapeutics, Inc., acquired stock options to purchase 5,000 shares of common stock on February 25, 2025.
NASDAQ
Dov A. Goldstein, a director of Coya Therapeutics, acquired stock options for 5,000 shares on February 25, 2025.
NASDAQ
Director Weinand Dieter reports acquisition of 5,000 Coya Therapeutics stock options.
NASDAQ
Director Wilbur L. Ross Jr. reports acquisition of stock options in Coya Therapeutics, Inc.
NASDAQ
Coya Therapeutics' Chief Financial Officer, David S. Snyder, was granted stock options for 140,562 shares on January 9, 2025.
NASDAQ
Coya Therapeutics CEO, Arun Swaminathan, was granted 240,964 stock options on January 9, 2025, which vest over 36 months.
NASDAQ
Coya Therapeutics' Chief Medical Officer, Fred Grossman, was granted 140,562 stock options on January 9, 2025.
NASDAQ
Director Howard Berman of Coya Therapeutics acquired 150,602 stock options on January 9, 2025, which vest over 36 months.
NASDAQ
Dov A. Goldstein, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
NASDAQ
Director Wilbur L. Ross Jr. of Coya Therapeutics acquired 5,000 stock options on January 1, 2025, which vest on the first anniversary of the grant date.
NASDAQ
A Coya Therapeutics director, Ann Lee, acquired 5,000 stock options on January 1, 2025, according to a recent SEC filing.
NASDAQ
Anabella Villalobos, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
NASDAQ
Dieter Weinand, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.
NASDAQ
Coya Therapeutics' Chief Financial Officer, David Snyder, purchased 1,800 shares of common stock at a price of $7.1858 per share on November 14, 2024.
NASDAQ
Coya Therapeutics CEO, Arun Swaminathan, purchased 5,000 shares of common stock at a price of $7.3594 per share on November 13, 2024.
NASDAQ
Coya Therapeutics' Chief Medical Officer, Fred Grossman, acquired 2,710 shares of common stock at a price of $7.37 per share on November 11, 2024.
NASDAQ
Coya Therapeutics CEO, Arun Swaminathan, purchased 5,000 shares of common stock at a price of $7.3378 per share on November 11, 2024.
NASDAQ
David S. Snyder, CFO of Coya Therapeutics, Inc., acquired 70,596 stock options on June 3, 2024, according to a Form 4 filing with the SEC.